32 results about "Peptide specificity" patented technology

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

To provide compositions and methods for increasing the stability of recombinant nanobodies. Also provided are recombinant Nanobodies comprising an IL-2 polypeptide that binds serum albumin, and uses thereof for treating cancer.SOLUTION: There is provided a recombinant Nanobody comprising a human serum albumin (HSA) binding polypeptide and an IL-2 polypeptide, wherein the HSA binding polypeptide specifically binds to an HSA epitope selected from the group consisting of epitope 1, epitope 2, epitope 3 and epitope 4.SELECTED DRAWING: Figure 16

This document relates to methods and materials involved in assessing and / or treating mammals having a caveolinopathy disease (e.g., immune-mediated rippling muscle disease (iRMD)). For example, methods and materials for detecting the presence of an autoantibody specific for a caveolae-associated protein 4 (cavin-4) polypeptide to identify a mammal as having iRMD as well as methods for treating a mammal identified having iRMD are provided. In some cases, cavin-4 polypeptides (and / or fragments thereof and / or variants thereof) can be used to detect the presence or absence of anti-cavin-4 polypeptide autoantibodies indicative of iRMD.

The invention relates to the technical field of biological medicine, in particular to a fibroblast-targeting phycocyanin conjugate, a sol preparation and application of the fibroblast-targeting phycocyanin conjugate, phycocyanin and targeting peptide are covalently linked through an SMCC cross-linking agent, LDL receptor-associated protein 1 highly expressed by fibroblast is specifically recognized through the targeting peptide, and efficient intracellular delivery is achieved; a water-soluble sol preparation carries phycocyanin to break through a cell barrier, and LRP1-rich fibroblasts in a wound are targeted and play a role in the fibroblasts. By inhibiting the EMT process of fiber cells, cell fibrosis and growth of wound bacteria are inhibited, scar formation is reduced, and wound healing is promoted. The defect that natural phycocyanin cells are poor in penetrability is overcome, scar-free healing is achieved by regulating Wnt5a / beta-catenin through targeted delivery, the effect is good, and application and popularization are convenient.

The present invention relates to adenoviral vectors and uses thereof wherein the viral capsid has been coated with a polypeptide capable of stimulating a peptide-specific immune response in an individual. Furthermore, the present invention relates to methods of treating diseases, such as cancer, by means of adenoviral vectors that have been coated with polypeptides capable of eliciting a peptide-specific immune response. The invention also relates to methods of coating adenoviral vectors by specific peptides and methods of identifying those peptides suitable for coating the capsid of an adenoviral vector.

The present invention relates to T cell receptors (TCRs), and in particular TCRs specific for peptides derived from melanoma associated antigen 4 (MAGE-A4). The invention also relates to antigen binding portions of said TCR, compositions comprising said TCR or portions, fusion proteins comprising said TCR or portions, nucleic acids and vectors encoding said TCR or portions, cells comprising said TCR or portions, and methods of treatment involving said TCR or portions.

The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

A multi-target DC vaccine based on tumor antigen epitope peptides and its application belong to the field of tumor immunotherapy technology. The vaccine comprises an hr-8 conjugate peptide, an immune adjuvant, a carrier, and an immune memory enhancer. The hr-8 conjugate peptide is a conjugate product formed by chemically linking an hr-8 targeting peptide with at least two different tumor antigen CTL epitope peptides. The immune adjuvant is a combined adjuvant system of the TLR9 agonist CpG ODN and the TLR3 agonist poly(I:C). The carrier is PLGA nanoparticles, and the immune memory enhancer is IL-7 and / or IL-15. This invention utilizes the specific binding of the hr-8 peptide to the DEC-205 receptor on the surface of dendritic cells to achieve efficient synergistic delivery and cross-presentation of multi-target antigens. The combined adjuvant and memory factor significantly enhance CTL activation and promote long-term immune memory formation, giving the multi-target DC vaccine advantages such as strong targeting, broad antigen coverage, and prolonged relapse-free survival.

The present disclosure provides a prophylactic or therapeutic agent for a benign tumor. Provided is a prophylactic or therapeutic agent for a benign tumor, which comprises a WT1 peptide, an analog thereof, or a nucleic acid molecule encoding the same. In a specific embodiment, the present disclosure provides a prophylactic or therapeutic agent for a benign tumor, which comprises a WT1 peptide, an analog thereof, or a nucleic acid molecule encoding the same. In a preferred embodiment, the prophylactic or therapeutic agent for a benign tumor (e.g., familial adenomatous polyposis) according to the present disclosure comprises a killer-type and / or helper-type WT1 peptide. In a further preferred embodiment, the aforementioned WT1 peptide is a WT1 126 killer peptide and / or WT1 35 helper peptide. In another aspect, provided are WT1 peptide-specific CTLs, a method for inducing WT1-specific helper T cells, and a method for inducing dendritic cells presenting a WT1 peptide.

The application discloses autoimmune disease specific polypeptides, specific antibodies and application, and polypeptides are at least selected from one polypeptide in the following amino acid sequences: CarSP-1: VFLCPWRAEGGQCcarPSLLFDLRDETRNV; CarSP-2: FLCPWRAEGGQCcarPS; CarSP-3: AEGGQCcarPSLLFDLR; CarSP-4: CcarPSLLFDLRDETRNV and CarSP-5: VFLCPWRAEGGQCcarPSLLFDLRDCTRNV, cys4&cys23bridge; in view of the threat of autoimmune diseases to human health and life treatment, the application will have broad application prospects for the diagnosis and treatment of autoimmune diseases.

A near-infrared imaging agent includes a targeting peptide that specifically binds to and / or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment, an optional spacer directly linked to the targeting peptide; and a near-infrared fluorophore that is directly or indirectly linked to the targeting peptide or optional spacer via a natural or non-natural linkage.

The present disclosure relates to multimers of a phosphatidylinositol-3 (GPC3)-specific peptide, a CD44-specific peptide, and an epithelial cell adhesion molecule (EpCAM)-specific peptide, and their use for the detection and treatment of epithelial cell-derived cancers, the epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and skin basal cell carcinoma. The present disclosure also relates to methods for monitoring the therapeutic response of a treated patient using the peptide multimers.

The invention provides a muscle-targeted adeno-associated virus capsid protein, an adeno-associated virus containing the muscle-targeted adeno-associated virus capsid protein, a vector and application. The present disclosure provides an adeno-associated virus capsid protein, which comprises a targeting peptide, and the targeting peptide comprises any one of the following amino acid sequences: SEQ ID NO: 1-19. According to the invention, a reasonable design and directed evolution combined method is adopted, and on the basis of a receptor integrin-RGD polypeptide specific binding principle, random amino acids are carried to adapt to construction and screening of the AAV vector of a capsid structure, so that the problems of poor stability of the capsid structure, change of histocompatibility and the like caused by direct insertion of a sequence are avoided; therefore, efficient transduction of muscular tissues is realized, and a reliable platform is provided for gene therapy.

The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and / or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1126 killer peptide and / or WT135 helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.

The invention belongs to the technical field of prevention and treatment of severely acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), and discloses an HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide, a polymer of the HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide and application of the HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide, and amino acid sequences of the HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide are shown as SEQ ID NO: 1-2. The HLA-E restricted CD8 < + > T cell epitope polypeptide provided by the invention can be applied to preparation of epitope peptide vaccines or induction of generation of epitope peptide specific CTL, so that the problem of low population coverage rate caused by HLA restriction of the existing vaccines is effectively solved, immune response coverage of wider crowds is realized through non-classical HLA-E molecules, and the HLA-E restricted CD8 < + > T cell epitope polypeptide can be applied to preparation of epitope peptide vaccines. The traditional Chinese medicine composition has the advantage of improving the universal immune response of people.

This invention discloses a biomarker for evaluating the immune status of COVID-19 vaccines and its application. The biomarker includes any one or a combination of at least two of the following SARS-CoV-2 viral peptides: M1, N16, N24, S15, S39, S44, S64, S82, S95, S104, or S115. This invention accurately identifies differences in peptide-specific antibody responses between asymptomatic and symptomatic patients. Through clustering heatmaps, it determines the differences in responses to peptides such as M1, N24, S15, S64, S82, S104, and S115 between vaccinated individuals and infected individuals. This effectively distinguishes between infected patients and vaccinated individuals, as well as between asymptomatic and symptomatic patients, providing a reference for COVID-19 treatment and peptide vaccine development.

The invention belongs to the field of biology, and discloses a calcitonin gene related peptide specific epitope peptide, an antigen, an antibody and a kit. The antigen epitope peptide is at least one of an antigen epitope peptide I with an amino acid sequence as shown in SEQ ID NO.1 and an antigen epitope peptide II with an amino acid sequence as shown in SEQ ID NO.2. An antibody obtained by immunizing an animal with an antigen obtained by using the antigen epitope peptide is used for qualitatively or quantitatively detecting the calcitonin gene-related peptide. The kit containing the antibody has good diagnostic sensitivity, specificity and repeatability, and can be used for preparing products for diagnosing migraine.

The application belongs to the technical field of biological medicine, and relates to a BCLAF1 protein Ser564 site phosphorylation antigen peptide, a specific antibody and a preparation method and application thereof. The application identifies BCLAF1 protein Ser564 as a key phosphorylation site through SIK2 kinase screening, and designs and synthesizes a phosphorylation antigen peptide based on the site. After immunizing animals, a polyclonal antibody specifically recognizing BCLAF1 Ser564 site phosphorylation modification is successfully prepared. The antibody has high sensitivity and strong specificity, is suitable for various detection platforms such as immunohistochemistry and immunoblotting, and can be used for evaluating tumor immunotherapy efficacy. The application provides a key tool for analyzing BCLAF1 phosphorylation regulation mechanism, and lays a theoretical foundation for developing an immune combined therapy strategy targeting a SIK2-BCLAF1-CCL5 axis.

The invention discloses application of CREKA modified nanoparticles in treatment of retinal vascular thrombosis, and relates to the technical field of nanoparticles. The nanoparticle contains a polylactic acid-glycolic acid copolymer as a carrier and entraps a recombinant tissue type plasminogen activator and perfluoropentane, the surface of the PLGA is modified with CREKA peptide, the CREKA peptide is used for targeting thrombus fibrin, the rtPA is used for thrombolysis, and the PFP is used for phase change under the ultrasonic effect to promote drug release. According to the invention, thrombus fibrin is specifically targeted through CREKA peptide, high-efficiency enrichment of a drug at a focus part is realized, low-intensity ultrasound is combined to trigger PFP phase change blasting and promote rtPA release, the thrombolysis effect is obviously superior to that of a traditional method, in-vitro experiments show that a thrombus structure is loose after thrombolysis of a PPrC group, and change of absorbance of supernate proves that the thrombolysis rate is the highest.

The present invention relates to an antigen binding protein that specifically binds to a melanoma associated antigen (MAGE) B2 antigen peptide expressed by a tumor, which is complexed with an MHC. The antigen binding proteins are provided for use in the treatment of cancers expressing MAGEB2. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins, and pharmaceutical compositions comprising the antigen binding proteins.

This invention belongs to the field of immunoassay and discloses an antigenic peptide phosphorylated at amino acid position 433 of CRTC2, a specific antibody, and its applications. Mass spectrometry analysis reveals for the first time the role of the CRTC2 Ser433 phosphorylation site in radiotherapy resistance, indicating that the phosphorylation level of CRTC2 Ser433 can serve as an indicator for predicting the radiosensitivity of liver cancer patients. Using the CRTC2 Ser433 phosphorylated antigenic peptide: CPHHRRVPLpSPLS, a specific phosphorylated antibody (CRTC2P-Ser433 antibody) is prepared for the first time. Radiosensitivity can be predicted through immunohistochemical staining scores, demonstrating both specificity and ease of detection.

This disclosure provides a composition comprising i) a pseudotyped retroviral vector particle or virus-like particle thereof comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its native receptor(s) and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for a tag of a tagged polypeptide, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, and b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and ii) said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of a target cell, thereby transducing the target cell with said retroviral vector particle or thereby inducing uptake of the virus-like particle into the target cell. A pharmaceutical composition thereof and an in vitro method for transduction of targets cells with said vector particle are also disclosed.

Disclosed herein are adoptive T cell therapies or T cell receptor (TCR) gene therapies from the treatment of cancer. The therapies utilize a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a MYD88 L265P peptide of SEQ ID NO: 2 in the context of HLA-B*07:02 having a high avidity to said peptide / HLA complex. Proteins corresponding to said TCR constructs and host cells, preferably, CD8+ T cells, comprising the TCR constructs are described, as well as the medical use of such nucleic acids, proteins or host cells, in particular, in the diagnosis, prevention and / or treatment of a MyD88 L265P expressing cancer such as a non-Hodgkin B-cell lymphoma selected from the group comprising diffuse large B-cell lymphoma (DLBCL), e.g., activated B-cell-like DLBCL (ABC-DLBCL) or pCNS DLBCL, cutaneous DLBCL, leg-type DLBCL or testicular DLBCL; lymphoplasmacytic lymphoma (LPL), e.g., Waldenström macroglobulinemia (WM); and IgM monoclonal gammopathy (IgM MGUS).

The invention belongs to the technical field of cytobiology and molecular biology, and relates to a cyclized fluorescent protein probe for specifically recognizing tubulin tau in body fluid based on affinity oligopeptide. According to the invention, two short peptides capable of specifically recognizing tau protein are used as sensing domains and can specifically bind to tau protein in body fluid. MCherry red fluorescent protein is selected as a template, cyclization rearrangement is carried out, and the affinity oligopeptide is connected to a new NC terminal to serve as a sensing domain of the probe. By utilizing the probe, the concentration of tau protein in body fluid can be quantitatively analyzed by quantifying the change degree of fluorescence. After amplification expression and purification of a prokaryotic system, the obtained probe keeps a considerable degree of linearity between fluorescence intensity change and tau protein concentration in a blood environment or a cerebrospinal fluid environment, and serum of an AD patient and serum of a healthy person can be basically distinguished. The probe has the advantages of low background noise, high contrast ratio, good specificity, high sensitivity, low price, simplicity in operation and the like.

The invention belongs to the technical field of biological medicines, and relates to a BCLAF1 protein Ser564 site phosphorylated antigen peptide, a specific antibody, and a preparation method and an application of the BCLAF1 protein Ser564 site phosphorylated antigen peptide. According to the invention, a BCLAF1 protein Ser564 is screened and identified as a key phosphorylation site through SIK2 kinase, a phosphorylation antigen peptide is designed and synthesized based on the site, and after an animal is immunized, a polyclonal antibody capable of specifically recognizing phosphorylation modification of the BCLAF1 Ser564 site is successfully prepared. The antibody has high sensitivity and strong specificity, is suitable for various detection platforms of immunohistochemistry, immunoblotting and the like, and can be used for evaluating the curative effect of tumor immunotherapy. According to the invention, a key tool is provided for analyzing a BCLAF1 phosphorylation regulation mechanism, and a theoretical basis is laid for developing an immune combination therapy strategy of a targeted SIK2-BCLAF1-CCL5 axis.

The present invention relates to the efficient delivery of anti-infective activity, immune modulators, or growth-promoting biomolecules directly to the gastrointestinal tract of animals via a biodelivery platform.SOLUTION: The biodelivery platform can be a genetically modified microorganism. Delivery can be achieved using Lactobacillus species fix in the gastrointestinal tract. The anti-infective activity can be a bactericidal or bacteriostatic peptide, an antibody or fragment thereof that specifically recognizes a pathogen, or a phage or lytic peptide derived from a phage that specifically targets a particular pathogen.SELECTED DRAWING: None

The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a Lactobacillus sp which colonizes the gastrointestinal tract. The anti-infective activity can be a bacteriocidal or bacteriostatic peptide, an antibody or fragment thereof which specifically recognizes a pathogen, or a phage, or a lytic peptide from a phage which specifically targets a certain pathogen.

The present invention provides a composition comprising i) a pseudotyped retroviral vector particle or virus-like particle thereof comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its native receptor(s) and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for a tag of a tagged polypeptide, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, and b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and ii) said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of a target cell, thereby transducing the target cell with said retroviral vector particle or thereby inducing uptake of the virus-like particle into the target cell. A pharmaceutical composition thereof and an in vitro method for transduction of targets cells with said vector particle are also disclosed.

Provided are a T cell receptor capable of recognizing an EBV antigen and the use thereof. The TCR comprises an α chain containing a variable region and / or a β chain containing a variable region, the variable region of the α chain containing a complementarity determining region 3 (CDR3) of which the amino acid sequence is as shown in SEQ ID NO: 4 or consisting of the CDR3 of which the amino acid sequence is as shown in SEQ ID NO: 4; and / or, the variable region of the β chain containing a CDR3 of which the amino acid sequence is as shown in SEQ ID NO: 7 or consisting of the CDR3 of which the amino acid sequence is as shown in SEQ ID NO: 7. The TCR can specifically bind to an EBV antigen short peptide. A T cell transcribing the TCR can specifically recognize an antigen short peptide presented by HLA-DP5 and can be specifically activated by tumor cells expressing HLA-DP5 and EBNA1, so as to generate a killing function.

The invention discloses a method for identifying RNA guanine quadruplex sites at a whole transcriptome level. The method comprises the following steps: (1) carrying out fragmentation treatment on RNA; (2) purifying RNA; (3) carrying out denaturation and renaturation reaction; (4) preparing a peptide-RNA compound; (5) centrifugal recovery and purification; (6) detecting the enrichment degree of RNA G4 by using a qPCR (quantitative polymerase chain reaction) method; and (7) carrying out library establishment and Illumina sequencing on the IP DNA subjected to enrichment degree detection, and carrying out bioinformatics analysis to realize the identification of the G4 locus at the whole transcriptome level. The whole method is based on peptide specificity self-assembly to enrich and separate G4, does not depend on magnetic beads, does not need a high-temperature digestion step, is simple in process, short in time consumption and strong in RNA fragmentation visualization effect, and is theoretically suitable for various animal cells.